Head to Head Survey: Bristol Myers Squibb (NYSE:BMY) versus Xeris Biopharma (NASDAQ:XERS)

Bristol Myers Squibb (NYSE:BMY – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Insider and Institutional Ownership

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 42.7% of Xeris Biopharma shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 4.3% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Bristol Myers Squibb and Xeris Biopharma”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bristol Myers Squibb $48.19 billion 2.60 $7.05 billion $4.54 13.50
Xeris Biopharma $335.41 million 5.84 $550,000.00 ($0.11) -97.73

Bristol Myers Squibb has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bristol Myers Squibb has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Bristol Myers Squibb and Xeris Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb 1 16 11 2 2.47
Xeris Biopharma 1 1 4 0 2.50

Bristol Myers Squibb presently has a consensus price target of $65.50, indicating a potential upside of 6.85%. Xeris Biopharma has a consensus price target of $13.20, indicating a potential upside of 22.79%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Bristol Myers Squibb.

Profitability

This table compares Bristol Myers Squibb and Xeris Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bristol Myers Squibb 18.87% 66.90% 14.74%
Xeris Biopharma -5.12% 338.21% 3.50%

Summary

Bristol Myers Squibb beats Xeris Biopharma on 9 of the 15 factors compared between the two stocks.

About Bristol Myers Squibb

(Get Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.